When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ObsEva SA (NASDAQ:OBSV) is down 24% premarket on light volume in reaction to its announcement that lead drug nolasiban failed to achieve the primary endpoint in a Phase 3 clinical trial, IMPLANT4, aimed at demonstrating that a single oral dose increased the pregnancy rate in women undergoing in vitro fertilization (IVF). The company has decided to terminate development for IVF and is exploring "repositioning" the oxytocin receptor antagonist.
More news on: ObsEva SA, Healthcare stocks news, Stocks on the move,